Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Beijing Tiantan Biological Products Gross Margin %?
Beijing Tiantan Biological ProductsSHSE:600161 75 Gross Margin % is 34.59% as of Mar. 2026, which is 30% below its 10-year median of 49.62. GuruFocus rates SHSE:600161 with a GF Score™ of 75/100 and a GF Value™ of ¥23.94 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 732 Biotechnology companies, Beijing Tiantan Biological Products ranks worse than 68.17% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Beijing Tiantan Biological Products had a gross margin of 34.59% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Beijing Tiantan Biological Products Gross Margin % Related Terms
Beijing Tiantan Biological Products Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600161 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Beijing Tiantan Biological Products's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tiantan Biological Products Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Tiantan Biological Products's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Beijing Tiantan Biological Products's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Beijing Tiantan Biological Products (SHSE:600161) has a Gross Margin % of 34.59% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Beijing Tiantan Biological Products and its competitors. This is 30% below median its historical median of 49.62. Over the past decade, Beijing Tiantan Biological Products' Gross Margin % has ranged from 41.64 to 54.70. According to the industry distribution chart, Beijing Tiantan Biological Products ranks #499 out of 732 companies in the Biotechnology industry, placing it in the top 68.2%.
Is Beijing Tiantan Biological Products' Gross Margin % too high?
Beijing Tiantan Biological Products' current Gross Margin % of 34.59% is 30% below median its 10-year median of 49.62. Over the past 10 years, this metric has ranged from a low of 41.64 to a high of 54.70. The Biotechnology industry median Gross Margin % is 60.91. Beijing Tiantan Biological Products' value of 34.59% is 43.2% below this industry median. Based on the distribution chart, Beijing Tiantan Biological Products ranks #499 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Beijing Tiantan Biological Products has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tiantan Biological Products' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Tiantan Biological Products ranks #499 out of 732 companies for Gross Margin %. This places Beijing Tiantan Biological Products in the lower half of its industry. The industry median Gross Margin % is 60.91. Beijing Tiantan Biological Products' value of 34.59% is 43.2% below this benchmark. Historically, Beijing Tiantan Biological Products' own Gross Margin % has ranged from 41.64 to 54.70 over the past decade. While the company's 10-year median is 49.62 vs. the industry median of 60.91, Beijing Tiantan Biological Products has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Tiantan Biological Products's current Gross Margin % of 34.59% is 43.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Beijing Tiantan Biological Products and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Tiantan Biological Products's current Gross Margin % is 34.59%, which is 30% below median its own 10-year median of 49.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tiantan Biological Products stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products (SHSE:600161) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥23.94, compared to a current price of ¥12.95 — trading 45.9% below its estimated fair value. The current Gross Margin % is 34.59%, which is 30% below median its 10-year median of 49.62 and 43.2% below the Biotechnology industry median of 60.91. Beijing Tiantan Biological Products' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Beijing Tiantan Biological Products (SHSE:600161), the current Gross Margin % is 34.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tiantan Biological Products (SHSE:600161) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products stock appears to be undervalued.
The current stock price of ¥12.95 is trading 45.9% below its estimated GF Value™ of ¥23.94.
GuruFocus considers Beijing Tiantan Biological Products to be Significantly Undervalued.
Key valuation signals for SHSE:600161:
Gross Margin %: 34.59% (30% below median its 10-year median of 49.62)
GF Value™: ¥23.94 vs. price of ¥12.95 (45.9% below fair value)
Industry Position: 43.2% below the Biotechnology median (#499 of 732)
No single metric tells the full story. See the SHSE:600161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tiantan Biological Products Business Description
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
75GF Score
Get the complete analysis for SHSE:600161
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600161 has been successfully added to your 
